Pyxis Oncology (PYXS) Capital Expenditures (2021 - 2024)
Pyxis Oncology (PYXS) posted quarterly Capital Expenditures of $237000.0 for Q1 2024, down 89.52% year-over-year from $2.3 million in Q2 2023, and up 103.65% quarter-over-quarter from -$6.5 million in Q4 2023.
Pyxis Oncology (PYXS) Capital Expenditures (2021 - 2024) Analysis & Trends
Pyxis Oncology (PYXS) has reported Capital Expenditures for 4 consecutive years, with $237000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Capital Expenditures fell 89.52% year-over-year to $237000.0; the TTM figure through Dec 2024 stood at $237000.0 (changed 0.0% YoY), while the FY2025 annual figure was $9000.0, down 96.2% from the prior year.
- Capital Expenditures advanced to $237000.0 in Q1 2024 per PYXS's latest filing, from -$6.5 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $5.0 million in Q4 2022 and bottomed at -$6.5 million in Q4 2023.
- Historically, Capital Expenditures has averaged $673909.1 across 4 years, with a median of $340000.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 6875.38% in 2023 and fell as far as 228.78% in 2023.
- Pyxis Oncology's Capital Expenditures stood at $371000.0 in 2021, then jumped by 1258.22% to $5.0 million in 2022, then tumbled by 228.78% to -$6.5 million in 2023, then jumped by 103.65% to $237000.0 in 2024.
- Business Quant data shows PYXS's Capital Expenditures at $237000.0 in Q1 2024, -$6.5 million in Q4 2023, and $61000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Pyxis Oncology | 197.09 Mn | 164.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 237,000.00 |
| Mar 31, 2024 | 237,000.00 |
| Dec 31, 2023 | -6.49 Mn |
| Dec 31, 2023 | -6.49 Mn |
| Sep 30, 2023 | 61,000.00 |
| Sep 30, 2023 | 61,000.00 |
| Jun 30, 2023 | 4.40 Mn |
| Jun 30, 2023 | 4.40 Mn |
| Mar 31, 2023 | 2.26 Mn |
| Mar 31, 2023 | 2.26 Mn |
| Dec 31, 2022 | 5.04 Mn |
| Dec 31, 2022 | 5.04 Mn |
| Sep 30, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | -65,000.00 |
| Jun 30, 2022 | -65,000.00 |
| Mar 31, 2022 | 340,000.00 |
| Mar 31, 2022 | 340,000.00 |
| Jun 30, 2021 | 371,000.00 |
| Jun 30, 2021 | 371,000.00 |